Abstract library

19 results for "p53".
#2707 Investigating the Crosstalk between MEN1, p53 and Notch Reveals Biomarkers of Formation of Primary Pancreatic Neuroendocrine Tumors
Introduction: Pancreatic neuroendocrine tumors (PNETs) comprise a heterogeneous group of endocrine tumors. Previous studies showed that mutations of p53 are extremely rare; whereas genetic changes of MEN1 frequently occur and are correlated with poor prognosis in PNET. Still, their roles in tumorigenesis remain elusive.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Dr Ylenia Capodanno
#3072 Rb and p53 Status Determination by Immunochemistry Is Complementary in Routine Practice to Genetic Testing of Neuroendocrine Neoplasms
Introduction: Rb and p53 status may help distinguishing well from poorly differentiated neuroendocrine neoplasms (NEN) and may predict response to chemotherapy. Studies correlating Rb/p53 genetic and immunohistochemistry were performed on high-quality frozen samples with high throughput techniques efficient for copy number determination. This situation differs from routine practice in which small deletions may be hard to detect on formalin-fixed paraffin-embedded (FFPE) samples with a gene panel approach.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: Dr Jerome Cros
#2865 Can the Efficacy of Etoposide-Platinum Chemotherapy Be Predicted by p53/pRb Status in Grade 3 Neuroendocrine Neoplasms (G3 NEN)?
Introduction: Etoposide-platinum (EP) chemotherapy has long stood as the reference treatment of grade 3 neuroendocrine neoplasms (G3 NEN). However, G3 NEN are heterogeneous, including well differentiated tumours (NET) and poorly differentiated carcinomas of large (LCNEC) or small (SCNEC) cell type, whose identification can be challenging and response to EP be very variable, usually low in NET.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Dr Louis de Mestier
Authors: Lacombe C, De Rycke O, Chen R, Colnot N, ...
#2842 Transformation to High Grade 3 (G3) Neuroendocrine Neoplasia (NEN) – Molecular Imaging, Pathologic Features and Patient Outcomes
Introduction: Transformation of lower grade to Grade 3 (G3) NEN potentially impacts prognosis & treatment options.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dr Grace Kong
Authors: Kong G, Callahan J, Prall O, Michael M, ...
#2991 Gastroenteropancreatic (GEP) Neuroendocrine Neoplasia G3 (NEN G3) According to 2019 WHO Classification: A Comprehensive Clinicopathological Characterization Including Mismatch Repair (MMR) Proteins, PDL1 Expression and KRAS/BRAF Status
Introduction: In the 2019 WHO FOR NEN’S classification NETG3 have been distinguished from poorly differentiated neuroendocrine carcinoma (NEC). They are heterogeneous group concerning prognosis and treatment benefit.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: MD Gonzalo Ruiz
Keywords: G3 NEN, PD-L1, KRAS, BIOMARKERS
#205 Integrated Genome-Wide DNA Methylation and mRNA Expression Analysis of Pancreatic NETs Identifies Differential Activation of the Hypoxia Inducible Factor (HIF) Pathway Between Low and Intermediate Grade Tumors
Introduction: This is the first study to integrate DNA methylation and mRNA expression analysis in NETs. It is a powerful approach with which to identify disrupted biological pathways in NET pathogenesis.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Dr Christina Thirlwell
#321 Role of VEGFR-2, P53, P53R2 and Ki-67 Expression in Metastatic Carcinoid Cancer
Introduction: Ki-67 expression is a well-known prognostic factor in neuroendocrine tumors. The role of modified expression of p53, p53R2 and VEGFR2 in this disease’s liver metastases has not been established.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Dr Ranyell Matheus Spencer
Authors: Spencer R, Costa W, Salvador H, Diniz A, ...
#463 Primary Neuroendocrine Tumor of the Parathyroid
Introduction: Parathyroids are derived from third and fourth branchial pouches and neuroendocrine C-cells originate for neighboring fifth branchial pouch. A close ontogenic relation between these embryonal pouches is illustrated in DiGeorge syndrome wherein there is an absence of parathyroid glands and C-cells. It is not known for certain if normal parathyroids contain NE cells. However, NETs of the parathyroid have been reported in two other cases (Medline search: 1966-2011).
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Mohammed Ahmed
Authors: Ahmed M, ...
Keywords: parathyroid NET
#558 MANECs Among Colorectal Signet Ring Cell Carcinomas
Introduction: The mixed adenoneuroendocrine carcinomas (MANEC, WHO 2010) are neoplasms with heterogeneous morphology, whose mixed nature may be difficult to recognize.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: MD Gratiana Hermann
#682 Neuroendocrine Tumors, Searching for New Prognostic Biomarkers
Introduction: Neuroendocrine tumors (NET) of the digestive system were once considered relatively rare, however, the incidence is increasing. New prognostic biomarkers are needed for assessment of tumor behavior to inform patient treatment and improve outcome. The proliferation marker, Ki-67, is used for NET grading. Although classified as low grade, some tumors actually develop metastases.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Biomarkers
Presenting Author: Helen Miller